Retatrutide and the FDA: where approval stands
Retatrutide's trial data gets wide coverage. Many readers are therefore surprised to learn that no doctor can prescribe it yet. This page sets out its current position, explains why the approval process is slow, and gives a sober view of the likely timeline.
On this page
Current approval status
As of August 2026, retatrutide holds no marketing approval in any country. The FDA has not cleared it for the United States. The EMA has not cleared it for the European Union. Whatever retatrutide exists today is either sold for research purposes or obtained by some path outside approved prescribing.
Where development has reached
The compound is in Phase 3. This is the last and biggest round of human studies, run before a company asks a regulator for approval. Eli Lilly's Phase 3 work goes under the name TRIUMPH. It is a family of large trials in separate populations: obesity on its own, obesity alongside type 2 diabetes, and obesity alongside heart disease. Several of these studies released results during 2025 and 2026. Under controlled conditions, mean weight fell by about 20 to 29 percent. Where in that band a study landed depended on who was enrolled and how long it ran.
The trial numbers summarise published research for educational purposes. They make no claim about the outcome for any individual.
Why approval is still pending
Every new medicine passes through three phases of human research. Phase 1 looks at basic safety in a small number of volunteers. Phase 2 tests whether the compound works and narrows down a dose range. Phase 3 then confirms safety and effect in thousands of participants over a longer span. Only when Phase 3 ends does the developer hand its complete dataset to a regulator. The regulator reviews it and then decides. The pace is deliberate. Its aim is to detect rare or slow-to-appear harms before a medicine reaches the general public.
The meaning of “research use only”
A research-use-only label tells you that the trials a regulator requires have not been completed. As a result there is no approved medical use. The label says nothing negative about the molecule's safety or quality. It is a legal and regulatory category, not a grade. Research material has not been tested or authorised for use in people, and a responsible supplier states this openly.
The likely approval timeline
In July 2026 Eli Lilly said it plans to submit retatrutide to the FDA in the first quarter of 2027. Regulatory review then normally runs from several months to roughly a year. On that basis, the earliest approval date discussed in public is late 2027, possibly stretching into 2028. Dates can shift. Approval by one regulator also does not carry over automatically to another. To see how retatrutide sits beside compounds that already have approval, read our retatrutide and tirzepatide comparison and our retatrutide and semaglutide comparison.
References
- ClinicalTrials.gov. Retatrutide (LY3437943): Phase 3 TRIUMPH studies. Trial records.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315.
- Eli Lilly and Company. Retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). Press release, 23 July 2026. investor.lilly.com.
Frequently asked questions
Did the FDA approve retatrutide in 2026?
No. In August 2026 it was an investigational compound still in Phase 3 trials, with no FDA approval.
Does retatrutide have EU approval?
No. The European Medicines Agency has not authorised it. Its status in the EU is investigational, the same as in the US.
When might retatrutide receive approval?
Eli Lilly has said it plans to submit to the FDA in the first quarter of 2027. A decision could follow in 2027 or 2028. The timeline may change.
Is retatrutide available as a legal medicine?
No. There is no approved prescription product. What is sold is research-use-only material, which has not been tested or approved for use in people.